CVS Health (CVS) FY2025 10-K Annual Report
CVS Health (CVS) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 10, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
CVS Health FY2025 10-K Analysis
Business Overview
- • Core business risk focus on compliance with extensive laws, regulations, and contractual requirements in healthcare sectors
- • Increased litigation exposure due to vertical integration strategy and expanded healthcare services
Management Discussion & Analysis
- • No revenue or profitability data disclosed in this MD&A section
- • Market valuation risk: $3.6B fair value decline in long-term debt with 100bp rate increase; no impact on operations
Risk Factors
- • Opioid litigation risk: $320 million accrual increase for ongoing opioid litigation matters in 2025
- • Geopolitical/macroeconomic exposure: Medicare Advantage segment served 37 million people, sensitive to CMS policy changes
CVS Health FY2025 Key Financial MetricsXBRL
Revenue
$402.1B
▲ +7.8% YoY
Net Income
$1.8B
▼ -61.7% YoY
Operating Margin
1.2%
▼ -113bp YoY
Net Margin
0.4%
▼ -80bp YoY
ROE
2.4%
▼ -376bp YoY
Total Assets
$253.5B
▲ +0.1% YoY
EPS (Diluted)
$1.39
▼ -62.0% YoY
Operating Cash Flow
$10.6B
▲ +16.8% YoY
Source: XBRL data from CVS Health FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on CVS Health
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.